Managing Psychotropic Medications

Ocupación

Categorías

Bienestar y Salud

1. What is the target diagnosis and symptom cluster? (e.g., MDD with insomnia, bipolar I acute mania, GAD with panic features) — default: specify required
2. Has the patient failed prior medication trials? If so, list agents, doses, durations, and reasons for discontinuation — default: unknown, obtain history
3. Is the patient pregnant, planning pregnancy, or breastfeeding? — default: assess at intake
4. Are there relevant medical comorbidities? (hepatic/renal impairment, cardiac disease, seizure disorder, obesity, diabetes) — default: review medical record
5. Current medication list including OTC, supplements, and recreational substances? — default: obtain from patient and PDMP
6. Any known drug allergies or intolerances? — default: verify with patient and chart
7. What is the patient's age group and weight? (impacts dosing, FDA indications, metabolism) — default: adult
8. What is the setting? (outpatient initiation, inpatient acute stabilization, transition to maintenance) — default: outpatient

Documents to Request

• Complete medication history with trial adequacy documentation (dose and duration)
• Recent laboratory results: CBC, CMP, TSH, lipid panel, HbA1c, prolactin (if antipsychotic history), lithium level, valproic acid level, drug levels as applicable
• ECG (baseline QTc if prescribing agents with QTc risk: ziprasidone, citalopram >20mg in elderly, thioridazine, IV haloperidol)
• PDMP query results
• Pharmacogenomic testing results if available (CYP2D6, CYP2C19, CYP3A4, HLA-B*1502)
• Prior adverse drug reaction documentation
• Weight, BMI, waist circumference, blood pressure, fasting glucose baseline

Step 1: Diagnostic Confirmation and Treatment Target Selection

Before prescribing, confirm the DSM-5-TR diagnosis with documented criteria. Identify the primary treatment target (symptom cluster driving the greatest impairment) and any secondary targets. Document the treatment hierarchy:

• First-line agents: Those with the strongest evidence base for the specific diagnosis (Level A evidence from RCTs and meta-analyses)
• Second-line agents: Adequate evidence with less robust data or greater side-effect burden
• Augmentation strategies: For partial responders to first-line monotherapy
• Treatment-resistant options: After failure of two or more adequate trials

For each diagnosis, reference the applicable guideline:

• MDD: APA Practice Guidelines, STAR*D algorithm, CANMAT guidelines
• Bipolar Disorder: APA Guidelines, ISBD Task Force recommendations
• Schizophrenia: APA Guidelines, PORT recommendations
• Anxiety Disorders: APA Guidelines, NICE guidelines
• PTSD: APA Guidelines, VA/DoD CPG

Step 2: Agent Selection and Informed Consent

Select the specific agent based on:

• Evidence base for the diagnosis
• Side-effect profile matched to patient characteristics (avoid weight-gaining agents in obese patients, avoid sedating agents when alertness is required, consider sexual side effects in relevant populations)
• Drug-drug interactions with current medications (use interaction checker — Lexicomp, Epocrates, or Micromedex)
• Cost and insurance formulary coverage
• Patient preference and prior experience
• Pharmacogenomic data if available (CYP2D6 poor metabolizers — reduce doses of fluoxetine, paroxetine, many TCAs; CYP2C19 poor metabolizers — reduce citalopram, escitalopram, clobazam)

Document informed consent discussion covering:

• Indication and expected benefits
• Common and serious side effects
• FDA Black Box Warnings (suicidality with antidepressants in patients <25, metabolic syndrome with atypical antipsychotics, Stevens-Johnson syndrome with lamotrigine, teratogenicity with valproate)
• Expected timeline to therapeutic response
• Risks of untreated condition

Step 3: Dosing, Titration, and Monitoring Schedule

Document the prescribing plan with specific parameters:

• Starting dose with rationale (start low and go slow in elderly, hepatic impairment, or high sensitivity to side effects)
• Titration schedule with specific dose increments and intervals (e.g., sertraline 50mg daily x 1 week, then 100mg daily x 4 weeks before efficacy assessment)
• Target dose range based on evidence (document that subtherapeutic doses do not constitute adequate trials)
• Maximum dose per FDA labeling and guidelines
• Adequate trial duration before determining non-response (typically 4-6 weeks at therapeutic dose for antidepressants, 4-6 weeks for antipsychotics, 7-14 days for benzodiazepines)

Monitoring Parameters by Drug Class

SSRIs/SNRIs: Baseline weight, sexual function inquiry, sodium level (elderly), bleeding risk assessment, suicidality monitoring (weekly for first 4 weeks in patients <25)

Atypical Antipsychotics: Baseline and periodic monitoring per ADA/APA consensus guidelines — weight and BMI (monthly x 3 months, then quarterly), fasting glucose and HbA1c (at 12 weeks, then annually), lipid panel (at 12 weeks, then every 5 years or annually if abnormal), blood pressure, waist circumference, prolactin if symptomatic, AIMS examination for tardive dyskinesia (every 6 months on antipsychotics, every 12 months if no risk factors)

Lithium: Serum level (trough, 12 hours post-dose) at steady state (5 days), then monthly x 3, then every 3-6 months. Renal function (BUN, creatinine, eGFR) and thyroid function (TSH) every 6 months. ECG at baseline if >40 years old. Target trough: 0.6-1.0 mEq/L for maintenance, 0.8-1.2 mEq/L for acute mania.

Valproate: Serum level at steady state, then every 6-12 months. CBC with platelets, LFTs at baseline and periodically. Pregnancy test before initiation in women of childbearing potential. Target trough: 50-125 mcg/mL.

Clozapine: REMS program enrollment required. ANC monitoring: weekly x 6 months, then biweekly x 6 months, then monthly. Metabolic monitoring as per atypical antipsychotic protocol. Troponin and CRP if myocarditis suspected.

Step 4: Response Assessment and Treatment Adjustment

At each follow-up, document:

• Symptom response using validated scales (PHQ-9, GAD-7, YMRS, PANSS, or CGI)
• Side effect assessment using a structured tool (e.g., GASS for antipsychotics, FIBSER, or UKU Side Effect Rating Scale)
• Adherence assessment (self-report, pill counts, serum levels)
• Functional improvement (work, relationships, self-care)

Decision framework:

• Full response: Continue current regimen, establish maintenance plan
• Partial response (>25% symptom improvement): Optimize dose to maximum tolerated, consider augmentation
• Non-response (<25% improvement after adequate trial): Switch within class or between classes, reassess diagnosis
• Intolerable side effects: Switch to alternative agent with different side-effect profile

Checkpoint B: Post-Draft Alignment (Mandatory)

1. Is the diagnosis confirmed with DSM-5-TR criteria before medication selection?
2. Is informed consent documented including risks, benefits, and alternatives?
3. Are monitoring labs ordered with specific timeframes per drug class guidelines?
4. Is the titration schedule specific (not "titrate as tolerated") with dose, increment, and interval?
5. Are prior adequate trials documented with dose, duration, and reason for failure?

Quality Audit

• Indication documented with DSM-5-TR diagnosis code
• Guideline-concordant agent selection with rationale
• Drug-drug interaction check documented
• Informed consent documented (risks, benefits, alternatives, Black Box Warnings if applicable)
• Baseline labs obtained before initiation (specific to drug class)
• Starting dose, titration schedule, and target dose range specified
• Monitoring schedule with specific lab tests and timeframes documented
• Pregnancy status assessed in women of childbearing potential (particularly for valproate, carbamazepine, lithium)
• PDMP queried for controlled substances
• Follow-up appointment scheduled with specific timeframe
• Side effect assessment tool identified
• Measurement-based care instruments selected (PHQ-9, GAD-7, etc.)
• Plan for inadequate response documented (next step in algorithm)

Guidelines

1. Never prescribe benzodiazepines as monotherapy for depression — always in combination with an antidepressant and with a documented plan for taper.
2. Always check PDMP before prescribing any Schedule II-V controlled substance and document the query.
3. An adequate antidepressant trial is defined as 4-6 weeks at the minimum therapeutic dose — dose optimization must occur before declaring a trial failed.
4. Do not combine two serotonergic agents without explicitly assessing serotonin syndrome risk (SSRI + tramadol, SSRI + triptan, SSRI + MAOI are high-risk combinations).
5. Document the rationale for off-label prescribing when the agent is not FDA-approved for the target indication.
6. For clozapine, ensure REMS enrollment and ANC monitoring are documented — clozapine is the only antipsychotic with Level A evidence for treatment-resistant schizophrenia.
7. In elderly patients, apply Beers Criteria — avoid anticholinergic agents, long-acting benzodiazepines, and tricyclic antidepressants as first-line options.
8. When discontinuing antidepressants or benzodiazepines, use a gradual taper schedule to prevent discontinuation syndrome or withdrawal seizures.